Ketamine and Propofol NeuroImaging

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
Keith M Vogt
Study ID
NCT07294092
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Anesthesia
  • Pain

Eligibility Criteria

Sex
ALL
Age
18 Years - 59 Years
Healthy Volunteers
Accepted

Interventions

  • Propofol — DRUG
    Subjects will receive an intravenous infusion of this drug, during portions of the study.
  • Ketamine — DRUG
    Subjects will receive an intravenous infusion of this drug, during portions of the study.
  • Peripheral Nerve Stimulation — DEVICE
    Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired with specific experimental events.

Study Details

This is a multi-visit which will collect MRI (pictures of the brain) and EEG (brain waves) data to determine changes in brain connectivity and brain activity for memory formation and pain perception while receiving the commonly-used anesthetic agents ketamine and propofol, both alone and in combination.

Key Dates

Start date
Apr 10, 2026
Status verified
May 2026
Primary completion
Aug 1, 2028
Completion
Aug 2, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Propofol, followed by propofol+ketamine (given at first visit)
    * Propofol, followed by propofol+ketamine at Visit 1 * Ketamine, followed by ketamine+propofol at Visit 3 * Propofol, followed by propofol+ketamine at Visit 5 * Ketamine, followed by ketamine+propofol at Visit 7 EEG will be done at either visits 1 and 3 or 5 and 7; fMRI will be done at the other two (non-EEG) visits.
  • Experimental: Ketamine, followed by ketamine+propofol (given at first visit)
    * Ketamine, followed by ketamine+propofol at Visit 1 * Propofol, followed by propofol+ketamine at Visit 3 * Ketamine, followed by ketamine+propofol at Visit 5 * Propofol, followed by propofol+ketamine at Visit 7 EEG will be done at either visits 1 and 3 or 5 and 7; fMRI will be done at the other two (non-EEG) visits.

Primary Outcome Measure

Explicit Memory Performance, comparing single-drug to drug-combination condition [ Time Frame: Visits 2, 4, 6, and 8. Visits spaced at least 1 week apart, are 1 hour in length, and are 12-36 hours after the preceding visit (1, 3, 5, and 7). ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of PittsburghPittsburghPennsylvania15213
Keith M Vogt, MD, PhD
[email protected]
4126473147

Find similar trials in Pittsburgh, PA

By research site
University of Pittsburgh· Pittsburgh, PA

Related Studies